Other languages IGC Pharma, Inc.

Equities

IGC

US45408X3089

Market Closed - Nyse Other stock markets 16:00:00 2024-05-14 EDT			5-day change	1st Jan Change
0.5538 ^USD	+6.50%		+8.76%	+96.36%

04-16	IGC Pharma, Inc Announces Interim Data from Its Phase 2 Clinical Trial Demonstrates Clinically Significant Reduction, Approaching Statistical Significance, in Agitation in Alzheimer?S At Week Two Compared to Placebo	CI
03-22	Aurora, Canopy Among Cannabis Stocks Rising After Germany Passes Partial Legalization Law	MT

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

IGC Pharma, Inc Announces Interim Data from Its Phase 2 Clinical Trial Demonstrates Clinically Significant Reduction, Approaching Statistical Significance, in Agitation in Alzheimer?S At Week Two Compared to Placebo	04-16
Aurora, Canopy Among Cannabis Stocks Rising After Germany Passes Partial Legalization Law	03-22
Aurora Cannabis, Canopy Growth Among Cannabis Stocks Rising After Germany Passes Partial Legalization Law	03-22
IGC Pharma, Inc Announces the Results of an Interim Analysis of its Ongoing Phase 2 Trial Investigating IGC-Ad1 as Treatment for Agitation in Dementia from Alzheimer?s Disease	03-20
Igc Pharma, Inc. Appoints Terry Lierman as Independent Director to Its Board of Directors	03-12
IGC Pharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	02-14
IGC Pharma Announces Tgr-63 Reduces Agitation in Alzheimer's Mouse Model	02-01
IGC Pharma, Inc. Provides Details on its Drug Candidate TGR-63	01-23
Igc Pharma, Inc. Activates Clincloud, One of 12 Sites in Ongoing Phase 2B Alzheimer?S Trial	01-17
Patent Granted to IGC Pharma for Groundbreaking Drug Formulation to Treat Agitation in Alzheimer's	12-19
IGC Pharma, Inc. Announces an Artificial Intelligence Collaboration with Los Andes University?s Center for Research and Training in Artificial Intelligence	12-06
IGC Pharma, Inc. Announces Master Agreement with University of Los Andes to Advance AI Initiatives	11-21
IGC Pharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	11-09
IGC Pharma Receives European Patent for Cannabinoid Pain Treatment	23-10-19
IGC Pharma, Inc. Reports Earnings Results for the First Quarter Ended June 30, 2023	23-08-10
IGC Pharma Expands Phase 2 Trial of IGC-Ad1 to Include the University of Puerto Rico	23-08-02
IGC Pharma, Inc. Presents 6 Posters on the Positive Impact of IGC-AD1 on Neuropsychiatric Symptoms in Dementia at the 2023 Alzheimer's Association International Conference	23-07-18
IGC Pharma, Inc. Reports Earnings Results for the Full Year Ended March 31, 2023	23-07-07
IGC Pharma to Raise $3 Million in Gross Proceeds From Private Placement	23-07-06
India Globalization Capital, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022	23-02-14

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages IGC Pharma, Inc.

Equities

IGC

US45408X3089

Other languages

Filters